INVEST IN VITA IMAGING TODAY!
Defy Cancer
$349,256.88 Raised
REASONS TO INVEST
Vita Imaging has developed patented, breakthrough decision support tools that provide Physicians with critical diagnostic information in real-time to decrease unnecessary biopsies and optimize treatment outcomes for patients. The company’s first product, AURA™ is an award-winning, non-invasive imaging device, which can be used by dermatologists to detect Melanoma & Non-Melanoma skin cancer (NMSC) within two seconds.
According to the American Academy of Dermatology, 1 in 5 Americans will develop skin cancer in their lifetime making skin cancer the most common cancer in the United States. It is estimated that approximately 9,500 people in the U.S. are diagnosed with skin cancer every day affecting over 3 million people per year.* Additionally, Vita’s products leverage Raman spectroscopy technology, which is a vertical projected to reach $2.3B this year.*
Vita Imaging has already applied to the FDA for market clearance for the Aura and is projecting completion of the regulatory process in late 2023 which is typically a major inflection point for life sciences companies. The company’s CEO is a Stanford engineering graduate and has a track record of taking a start-up high tech company public on the NASDAQ and achieving a market cap of over $2 billion.
the pitch
Vita Imaging is poised to revolutionize the way physicians and health care professionals detect and diagnose skin cancer. In partnership with leading field scientists and physicians, the company is advancing towards FDA market clearance and commercial launch for its first screening system, AURA™ – a licensed, patent-protected diagnostics platform technology capable of generating accurate, objective results in real-time.
Please see the offering memorandum for information regarding the company's IP licensing agreements.
The Problem & Our Solution
Eradicating Today’s Staggering Skin Cancer Statistics With Cutting-Edge Diagnostic Technology
In the United States alone, it is estimated that 9500 people are diagnosed with skin cancer every day and one in every five people will develop skin cancer by the age of 70 (source). Currently, skin cancer is the most common form of cancer in the U.S. costing the healthcare system $8.1B annually (source).
According to the American Cancer Society, the five year survival rate for melanoma is 99%, when detected early (source). However, most healthcare providers still rely on visual inspection of suspicious lesions, sometimes with dermatoscopes for magnification, to identify potential skin cancer concerns, leading many physicians to excise or biopsy lesions as a precautionary procedure. These biopsies cost an estimated $1.6B annually, but even so, 95% of suspicious lesions are later found to be benign.
*The aura product is pre-FDA approval and is not yet available on the market.
In 2014, the Centers for Disease Control released “The Surgeon General’s Call to Action to Prevent Skin Cancer, which identified Skin Cancer as the most commonly diagnosed cancer in the United States and established skin cancer prevention as a high priority for this country” (source). Heeding this call to action, Vita Imaging believes there is an urgent need for physician support tools such as AURA™, which can improve diagnostic accuracy and significantly reduce the need for invasive and costly biopsies. AURA™ works by utilizing proven Raman spectroscopy technology to differentiate between benign and malignant lesions, and provide nearly instantaneous results. It’s also non-invasive and requires little training to use, meaning it can be quickly and easily deployed in any dermatological clinic.
The Market & Our Traction
Securing Proven Technology Status With Clinical Data and Pending FDA Market Clearance
Vita Imaging’s AURA™ device is coming to market following 20 years of extensive research and development by the British Columbia Cancer Agency Research Center and the University of British Columbia. The company has an exclusive license from both entities, and is backed by a comprehensive patent portfolio, which will facilitate development of future products from platform technology.
*The aura product is pre-FDA approval and is not yet available on the market.
To date, the Aura has been tested in comprehensive clinical studies – including the largest known study using Raman technology for skin cancer detection – and has successfully passed all product performance and safety tests. Through this process, we have demonstrated that AURA™ exceeds all FDA benchmarks, paving the way for full clearance and commercialization as a Class 3 medical device.
*The aura product is pre-FDA approval and is not yet available on the market.
In anticipation of commercial launch in multiple international markets, Vita Imaging will partner with key industry opinion leaders, distributors, physicians, clinics, hospitals, and other providers, which will allow us to further establish market leadership and credibility within the global healthcare community.
Why Invest
Invest in Life-Saving Technology Developed By Leading Scientists and Physicians
Skin cancer is a worldwide epidemic with significant health, economic, and societal consequences. According to the World Health Organization, at least 132K new melanomas are diagnosed each year, and the incidence of skin cancers has risen in recent decades (source). In order to begin improving these outcomes, Vita Imaging believes that the time to invest in objective, accurate diagnostic tools is now.
Over the next five years, the company will be focused on optimizing growth and marketing outreach with a goal of deploying our technology where it is needed most and defying cancer on a worldwide scale. Thank you for investing in our mission on StartEngine!
ABOUT
HEADQUARTERS
5390 Hellyer Avenue
San Jose, CA 95138
WEBSITE
View Site
Vita Imaging Inc. is a medical device company developing cutting-edge cancer detection and diagnostic technology. The company has already submitted an application seeking FDA clearance for their lead product, AURA™, a skin cancer (Melanoma & Non-Melanoma) detection device. The FDA review is in progress, with target completion by the end of 2023. To expand its market reach, Vita Imaging will seek Regulatory approval in additional markets including: Canada, the European Union (EU), and Australia.
TEAM
Thinh Quy Tran
Chairman and CEO
He was previously the Founder, Chairman, & CEO of Sigma Designs since its inception in 1982 – which he built from a humble start-up into a multi-billion dollar publicly traded NASDAQ company – making him one of the longest serving CEOs on the NASDAQ. Mr. Tran also has extensive experience raising capital, executing M&A transactions, and providing guidance to many start-ups.
Prior to Sigma Designs, Mr. Tran was employed by Amdahl Corporation and Trilogy Systems Corporation, leaders in the IBM mainframe computer market. Mr. Tran holds a B.S.E.E. from the University of Wisconsin & M.S.E.E. from Stanford University.
Maria Victoria Reade
COO
Dzung Kim Tran Wright
Interim CFO
Before joining Vita Imaging, Dzung held senior finance roles at Vivus Inc., Controlnet Inc., Foneweb Inc., and Microlambda Wireless Inc. She has a proven track record of success in leading and managing financial teams, and she has a deep understanding of financial reporting, analysis, and planning.
Dzung is a graduate of San Jose State University and holds a Bachelor's degree in Business Administration and Accounting.
TERMS
Vita Imaging
Overview
PRICE PER SHARE
$5.70
DEADLINE
Jul 17, 2023
VALUATION
$39.94M
FUNDING GOAL
$15k - $5M
Breakdown
MIN INVESTMENT
$245.10
MAX INVESTMENT
$4,999,994.40
MIN NUMBER OF SHARES OFFERED
2,631
MAX NUMBER OF SHARES OFFERED
877,192
OFFERING TYPE
Equity
ASSET TYPE
Common Stock
SHARES OFFERED
Common Stock
Maximum Number of Shares Offered subject to adjustment for bonus shares
*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.
Time-Based Perks
Friends and Family - First 72 hours 10% bonus shares
Early Bird Bonus - Next 96 hours - 5% bonus shares
Volume-Based Perks
Tier 1 Perk – Invest $500 and receive a custom-made skin lesion ruler with logo that can be used to check your moles and see if they are changing, and 2 logo branded silicone UV wrist bands that change color in the sun as a reminder to apply sunscreen.
Tier 2 Perk – Invest $2,500 and receive the skin lesion ruler, UV wristbands, USB drive, +3% bonus shares.
Tier 3 Perk – Invest $5,000 and receive the skin lesion ruler, UV wristbands, USB drive, +5% bonus shares.
Tier 4 Perk – Invest $10,000 and receive the skin lesion ruler, UV wristbands, USB drive, +10% bonus shares.
*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.
The 10% StartEngine Owners' Bonus
Vita Imaging, Inc will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $5.70/ share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $570. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any).
Irregular Use of Proceeds
The Company will not incur irregular use of proceeds.
ALL UPDATES
05.28.23
The ABCDEs of Skin Cancer
Melanoma is one of the deadliest forms of skin cancer, but it's also one of the easiest to prevent. Identifying melanoma is as easy as ABCDEs: asymmetry, border, color, diameter, and evolving.
Asymmetry: do both halves of the mole match?
Border: are the edges uneven, irregular, or notched?
Color: are there odd colors or many shades (brown, black, blue, red, pink, or white)?
Diameter: is the size larger than 6mm (1/4 inch) or roughly that of a pencil eraser?
Evolution: has there been a change in size, shape, color, or feel? Has it become itchy, or has it a burning or tingling feeling?
Performing regular skin checks at home is important to catch skin cancer before it becomes life-threatening. Be sure to look for odd colors, larger sizes, and changes in shape or texture. Knowing what to look for can save your life.
Remember, when it comes to skin cancer, early detection is key. If you see something on your skin, don't panic. While some moles or lesions may be cancerous, most are not. But it's always best to have them checked by a professional. With annual skin checks, you can catch potential issues before they become a problem.
05.24.23
May is Skin Cancer Awareness Month
Did you know that May is Skin Cancer Awareness Month? With over 5 million cases diagnosed in the United States each year, skin cancer is America’s most common cancer. The good news is, it is also one of the most preventable cancers.
Most skin cancers are caused by exposure to UV rays, which can damage your skin in as little as 15 minutes without protection – even on overcast days. It can happen to anyone, at any age, which is why wearing sunscreen every time you go outside is crucial.
This month, let’s join together to promote skin cancer awareness and help prevent unnecessary deaths. Take part in the #SkinCheckChallenge on social media, share your #ThisIsSkinCancer story, and support lifesaving programs. Together, we can make a difference.
05.20.23
Last Chance for Bonus Shares!
We are pleased to announce that Vita Imaging has exceeded $150,000 in investments in the first 48 hours of our crowdfunding campaign. We are blown away by the incredible support we've received and can't wait to change the game in healthcare.
But the clock is ticking! You can be a part of transforming global patient care, but don't wait too long. Invest before Saturday, May 20, 2023, at 9:00am PST to receive 10% bonus shares. Join us as we deploy our technology where it's needed most and defy cancer on a worldwide scale.
Have questions about Vita Imaging? Comment on the campaign page, and our team will get back to you.
05.19.23
Last Chance for Bonus Shares!
We are pleased to announce that Vita Imaging has exceeded $150,000 in investments in the first 48 hours of our crowdfunding campaign. We are blown away by the incredible support we've received and can't wait to change the game in healthcare.
But the clock is ticking! You can be a part of transforming global patient care, but don't wait too long. Invest before Saturday, May 20, 2023, at 9:00am PST to receive 10% bonus shares. Join us as we deploy our technology where it's needed most and defy cancer on a worldwide scale.
Have questions about Vita Imaging? Comment on the campaign page, and our team will get back to you.
Stack Owner's Bonus & Rewards!
Members get an extra 10% shares in addition to rewards below!
REWARDS
$245
Earn 10% Bonus Shares
Earn 10% bonus shares in this investment and all eligible investments for an entire year. If you are not already an Owners bonus holder, you can join now, for $275, billed annually.
$500
Tier 1 Perk
Invest $500 and receive a custom-made skin lesion ruler with logo that can be used to check your moles and see if they are changing, and 2 logo branded silicone UV wrist bands that change color in the sun as a reminder to apply sunscreen
$2,500
Tier 2 Perk
Invest $2,500 and receive the skin lesion ruler, UV wristbands, USB drive, +3% bonus shares.
$5,000
Tier 3 Perk
Invest $5,000 and receive the skin lesion ruler, UV wristbands, USB drive, +5% bonus shares.
$10,000
Tier 4 Perk
Invest $10,000 and receive the skin lesion ruler, UV wristbands, USB drive, +10% bonus shares.
JOIN THE DISCUSSION
0/2500
Bhavik Maheshbhai Barot
13 days ago
What is your expected growth once FDA approval is granted? Would every single dermatologist want to have this instrument? What is the revenue model?
1
0
Vinh Tran
13 days ago
Early detection is critical in beating cancer - this could revolutionize how doctors are able diagnose and treat patients. Excited to see this experienced team take this challenge head on.
1
1
Bhavik Maheshbhai Barot
13 days ago
What sets Aura apart from existing solutions for skin cancer detection, how does it differentiate itself, and why is it considered a disruptive technology in the field?
1
0
James Henderson
13 days ago
Is this the same device that was developed by Verisante Technology in 2014?
1
0
Michael Helm
13 days ago
Differentiated medical device that can improve society. Company maintains portfolio of patents. Experienced team: notable CEO, COO (Go Vols!), and scientific partners. Valuation seems a little high, but Form C justification for it is fair (10% bonus shares doesn't hurt). In short, if management executes, I think Vita Imaging has a favorable risk-reward profile.
Look forward to updates, FDA approval, and eventual profitability!
God bless.
1
0
Eric Krieg
14 days ago
To me this is not just about trying to make money. I'm investing partly out of humanitarian interests. I've had friends die of cancer, I have had cancerous tissue removed from my body. I want some of my investment money fighting cancer
1
0
Adam Sampson
8 INVESTMENTS
15 days ago
Have you started generating revenue? With being pre-FDA approval the valuation seems a bit steep, but I love the concept.
1
0
Adam Forster
15 days ago
Can you provide more definitive comparisons between a biopsy and your diagnostic in terms of reimbursement/cost, time to results and accuracy?
1
0
Paul Dodd
4 INVESTMENTS
15 days ago
If you invest $10 million you would probably own a substantial portion of the company, which would equate to owning the company and thus any property including intellectual. Does depend on employee, founders and investors external investors and creditors.
1
0
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
Ameersing Luximon
6 days ago
1
0